The INHBE Knockout SK-HEP-1 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal population of SK-HEP-1 cells bearing targeted disruption of the human INHBE gene. This loss-of-function model enables investigation of inhibin beta E subunit function within a liver adenocarcinoma background. The polyclonal format provides a heterogeneous knockout pool, suitable for studying gene function without clonal selection bias. These cells serve as a powerful tool for dissecting INHBE-dependent signaling pathways and phenotypic outcomes in hepatocellular carcinoma research.
The parental SK-HEP-1 cell line was originally established from the ascites of a patient with liver adenocarcinoma and exhibits dual epithelial and endothelial characteristics. This unique phenotype makes SK-HEP-1 a widely used model for hepatocellular carcinoma, particularly in studies of tumor metastasis, angiogenesis, and the interplay between epithelial and mesenchymal traits. The cell line??s endothelial-like features also render it valuable for investigating transendothelial migration and metastatic dissemination. INHBE knockout in this context allows direct assessment of activin E??s contribution to these malignancy-associated properties.
INHBE encodes the inhibin beta E subunit, which dimerizes to form activin E, a member of the TGF-beta superfamily. Activin E signals by binding to the type II receptor ACVR2B, which recruits and phosphorylates the type I receptor ALK4. This initiates intracellular signaling through SMAD2 and SMAD3 phosphorylation, leading to complex formation with SMAD4 and nuclear translocation. The activated SMAD complex transcriptionally regulates downstream genes, including CDKN1A (p21) for cell cycle control, PEPCK and G6PC for hepatic gluconeogenesis, and BCL2 family members for apoptosis. Upstream regulators such as TGFB1, insulin, FOXO1, and HNF4A modulate INHBE expression, placing activin E at a nexus of metabolic and growth factor signaling.
Disruption of INHBE in SK-HEP-1 cells provides a relevant model for dissecting activin E??s role in liver metabolism, hepatocellular carcinoma progression, and metastasis. The SK-HEP-1 background permits study of activin E-mediated SMAD2/3 signaling in a cell line that mimics both epithelial tumor cells and vascular endothelial cells. This dual character is especially advantageous for metastasis research, as the knockout cells can be employed in transwell migration, invasion, and tight junction integrity assays. Moreover, the model supports metabolic studies, given the gene??s involvement in hepatic glucose production through regulation of gluconeogenic enzymes like PEPCK and G6PC.
Researchers can apply the INHBE Knockout SK-HEP-1 Polyclonal Cells in a variety of experimental workflows. Western blotting and phospho-specific antibodies enable quantification of SMAD2/3 activation status, while RT-qPCR and RNA-seq provide transcriptional profiling of INHBE-dependent gene networks. Functional assays, including cell proliferation, apoptosis with annexin V staining, and glucose output measurements, elucidate the phenotypic consequences of activin E loss. The polyclonal pool is suitable for drug target validation for non-alcoholic fatty liver disease, obesity, and metabolic syndrome, and for screening compounds that modulate TGF-beta/activin signaling. For further information or technical support regarding these knockout cells, please contact Ascent Research.
